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Background: Recent reports have suggested that angioplasty, with and without stenting (PTA/S), may have a lower
perioperative mortality rate than open surgery for revascularization of acute (AMI) and chronic mesenteric ischemia
(CMI). It is unclear if there has been nationwide adoption of this methodology or whether there is actually a mortality
benefit.
Methods:We identified all patients undergoing surgical (bypass, endarterectomy, or embolectomy) or PTA/S mesenteric
revascularization from the Nationwide Inpatient Sample from 1988 to 2006. A diagnosis by International Classification
of Diseases, 9th Revisioncoding of AMI or CMI was required for inclusion. We evaluated trends in management during
this period and compared in-hospital death and complications between surgical bypass and PTA/S for the years 2000 to
2006.
Results: From 1988 to 2006, there were 6342 PTA/S and 16,071 open surgical repairs overall. PTA/S increased steadily,
surpassing all surgery for CMI in 2002. PTA/S for AMI has also increased and surpassed bypass in 2002 but has not
surpassed all surgical procedures for AMI even in 2006. The mortality rate was lower after PTA/S than after bypass for
CMI (3.7% vs 13%, P< .01) and AMI (16% vs 28%, P< .01). Bowel resection wasmore common after bypass than PTA/S
for CMI (7% vs 3%, P < .01). This subgroup showed an increased in-hospital mortality rate for both repair types (54%
and 25%, respectively).
Conclusion: PTA/S is being used with increasing frequency for revascularization of CMI and AMI. The lower in-hospital
mortality rate for patients, as they are currently being selected, shows that PTA/S is appropriate therapy for selected
patients with CMI. Longitudinal data are needed to determine the durability of this benefit. The greater proportion of
patients undergoing bowel resection with bypass for AMI suggests a more advanced level of ischemia in this group,
making comparison with PTA/S difficult. However, PTA/Smay be useful in selected patients with AMI and appropriate
anatomy. Further data with greater detail regarding symptomatology and anatomy will clarify appropriate patient
selection. (J Vasc Surg 2009;50:341-8.)Mesenteric ischemia requiring revascularization is asso-
ciated with high mortality in both chronic and acute forms.
Open surgical treatment with bypass, endarterectomy, or
embolectomy has been the standard for many years. Revas-
cularization for chronic mesenteric ischemia (CMI) is typ-
ically performed in elderly patients with extensive athero-
sclerotic disease and malnutrition. Given the rarity of the
disease, there are few reported series with large numbers of
patients undergoing surgery for CMI. Results from these
relatively high-volume centers of excellence have operative
mortality rates of up to 12%.1-7 Derrow et al8 reported
national outcomes for surgical revascularization of CMI
from the Nationwide Inpatient Sample (NIS), revealing an
in-hospital mortality rate of 15%. A few articles have re-
ported large numbers of patients with acute mesenteric
ischemia (AMI) undergoing revascularization. Revascular-
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An increasing number of small cohorts have been re-
ported in whom angioplasty, with or without stenting
(PTA/S), has been used for treatment of CMI, with mor-
tality rates similar to surgery in some reports and lower than
surgery in others.12-17 Several small case series have de-
scribed using PTA/S for treatment of AMI.18-22 The na-
tional adoption of PTA/S for CMI and AMI is largely
unknown. It is also unclear if PTA/S has a short-term
mortality benefit compared with surgery. To address this,
we evaluated trends inmanagement of CMI and AMI using
surgery or PTA/S between 1988 and 2006 and used a
national hospital administrative database to compare in-
hospital outcomes in the most recent years.
METHODS
Data sample. The Nationwide Inpatient Sample
(NIS) was used for this study. The NIS is maintained by the
Healthcare Cost and Utilization Project (HCUP) of the Ag-
ency for Healthcare Research and Quality. The database is
a 20% all-payer sample of hospital stays and contains sam-
pling weights to allow for stratified calculation of total
population estimates. The years 1988 to 2006 were used
for trend analysis, whereas comparisons between PTA/S
and surgery were limited to the years 2000 to 2006 when
PTA/S became commonplace. Study approval was ob-
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Deaconess Medical Center. Data use agreements for use of
the NIS data were made with HCUP.
Queries were performed with SAS 9.1 statistical soft-
ware (SAS Institute, Cary, NC) using the International
Classification of Diseases, 9th Revision (ICD-9) diagnosis
and procedure codes. Initial case selection required a pri-
mary admission diagnosis of acute (557.0) or chronic mes-
enteric ischemia (557.1) combined with a procedure code
of mesenteric angioplasty, with and without stent place-
ment (39.50, 39.90), or open mesenteric surgical proce-
dures including mesenteric bypass (39.26, 38.36, 38.46),
mesenteric embolectomy (38.06), or mesenteric endarter-
ectomy (38.16). The analysis excluded patients undergoing
aortic reconstruction and those 18 years.
Total population estimates were calculated per year of
hospitalization. The primary outcome was in-hospital
death. Secondary outcomes included need for bowel resec-
tion and complications including acute renal failure, acute
myocardial infarction, and others as defined by ICD-9
coding for complications Appendix (online only).
Statistical analysis. Statistical analysis was performed
using survey analysis programs with Stata 8 software
(StataCorp LP, College Station, Tex). Population esti-
mates are reported by applying the sampling weight for
each observation within Stata calculations. Means and stan-
dard deviations are reported for parametric data and me-
dian values and ranges for nonparametric data. Statistical
significance was assigned at P .01. Comparisons between
cohorts were done using the Wilcoxon ranked sum test for
nonparametric continuous data, the t test for parametric
continuous data, and the 2 test for categoric and numeric
data. Groups were stratified by diagnosis (AMI vs CMI)
Fig 1. Procedure volume for revascularization of chron
angioplasty, with or without stenting (PTA/S), compareand by revascularization method.Univariate and multivariate logistic regression was per-
formed using all demographic and comorbidity data as
potential risk factors. Procedure complications were not
included in multivariate analyses. The need for a bowel
resection was included as an independent predictor variable
in analysis of AMI (but not CMI) because this was consid-
ered more likely to be a reflection of the pre-existing extent
of ischemia at the time of revascularization rather than a
complication of the revascularization procedure. Multivar-
iate analysis was performed by backwards selection of risk
factors meeting statistical significance at the P  .10 level
on univariate analysis.
RESULTS
Overall. From 1988 to 2006, there were 6342 PTA/S
and 16,071 open surgical repairs. Between 2000 and 2006,
64.5% of patients diagnosed with AMI underwent open
surgery vs 35.5% for PTA/S, whereas patients with CMI
more often were treated with PTA/S (61.9% vs 38.1%).
Overall revascularization for CMI has increased over time
(Fig 1), but there has been relatively little change for AMI
(Fig 2). PTA/S increased over time for both diagnoses and
by 2002 had surpassed surgery for CMI and more than
doubled it by 2005. For AMI, PTA/S has surpassed bypass
and embolectomy individually, but surgical revasculariza-
tion in general remains the predominant treatment. Of
note, the proportion of patients with atrial fibrillation or
atrial flutter decreased over time from amaximum of 38% in
1994 to 24% in 2006.
Over time, the overall mortality rate for CMI and AMI
decreased (test of trend, P .001; Figs 3 and 4). After the
esenteric ischemia (CMI) by percutaneous transluminal
h open repairs from 1988 to 2006.ic myear 2000, when endovascular therapy was more com-
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tion was significantly lower than before this time period
(CMI, 8% vs 15%, P .001; AMI, 30% vs 49%, P .001).
CMI from 2000 to 2006. Patients undergoing revas-
cularization for CMI from 2000 to 20006 were generally
older women with multiple comorbidities. Those undergo-
ing PTA/S were older, more likely men, and had higher
rates of comorbidities (Table I). The surgical procedure
Fig 2. Procedure volume for revascularization of acut
angioplasty, with or without stenting (PTA/S), compare
Fig 3. Mortality rate after percutaneous transluminal an
surgical repair for chronic mesenteric ischemia (CMI) frperformed for CMI was overwhelmingly bypass (93%)compared with endarterectomy (4%) or embolectomy
(3%). Mortality was 3.7% after PTA/S and 15% after open
surgical repair (P  .001). Mortality after PTA/S was
significantly lower when the comparison was limited to
bypass (13% P  .001) and the higher mortality seen in
those undergoing endarterectomy (31%) or embolectomy
(69%) was excluded. The mortality differences for male vs
female for PTA/S (4% vs 4%, P .72) or open repairs (14%
senteric ischemia (AMI) by percutaneous transluminal
h open repairs from 1988 to 2006.
lasty, with or without stenting (PTA/S), compared with
988 to 2006.e megiopvs 16%, P  .66) were not significant (Table II).
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compared with bypass (38%, P  .001), with significant
differences in cardiac and respiratory complications (Table
III). PTA/S had approximately half the rate of acute renal
Fig 4. Mortality rate after percutaneous transluminal an
surgical repair for acute mesenteric ischemia (AMI) from
Table I. Baseline characteristics of patients undergoing an
repair for chronic and acute mesenteric ischemia from 200
Variable
Chronic mesenteric ischem
PTSA/S Surgerya
Patients, No. (%) 3455 (61.9) 2128 (38.1)
Age, median (range), y 74 (24-97) 68 (29-99)
60, % 15 32
60-69, % 23 28
70-79, % 37 30
80, % 25 11
Female, % 74 79
Comorbidities, %
Hypertension 66 51
PVD 40 32
CAD 39 26
AFib/flutter 16.5 14.9
Prior MI 8.3 6.0
CHF 17.5 10.5
Diabetes mellitus 19 12
COPD 25 27
Chronic renal disease 6.3 1.2
CVD 6.9 7.7
Charlson, mean  SD 1.3  1.1 1.0  1.0
Bowel resection, % . . . . . .
AFib, Atrial fibrillation; CAD, coronary artery disease; CHF, congestive he
disease; MI, myocardial infarction; PTA/S, percutaneous transluminal angi
deviation.
aSurgery includes bypass, endarterectomy, or embolectomy.
bStatistical significance set at P  .01.failure and need for bowel resection. Mortality in thoseundergoing bowel resection was significantly increased for
all patients regardless of the revascularization method com-
pared with those without a bowel operation (PTA/S, 25%
vs 3.1%, P  .001; bypass, 54% vs 10%, P  .001). Length
lasty, with or without stenting (PTA/S), compared with
8 to 2006.
lasty, with or without stenting, compared with surgical
2006
Acute mesenteric ischemia
Pb PTSA/S Surgerya Pb
. . . 1857 (35.5) 3380 (64.5) . . .
.001 72 (26-96) 72 (21-99) .53
.001 24 26 .34
.05 25 22 .36
.01 31 33 .62
.001 21 19 .52
.05 70 66 .14
.001 56 46 .01
.01 33 13 .001
.001 34 19 .001
.49 23.6 38.7 .001
.17 6.4 4.7 .23
.01 22.1 22.6 .85
.01 18 17 .73
.40 29 23 .06
.001 9.8 3.5 .001
.61 4.7 5.9 .41
.001 1.4  1.3 0.9  1.1 .001
. . . 28.1 47.8 .001
ure; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular
, with or without stenting; PVD, peripheral vascular disease; SD, standardgiopgiop
0 to
ia
art fail
oplastyof stay was shorter after PTA/S than bypass, with a median
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P  .001). Discharge to home was more common after
PTA/S (87%) vs bypass (79%, P  .01).
On multivariate analysis, mortality was still fivefold to
sixfold higher with bypass compared with PTA/S (Table
Table II. Mortality after angioplasty, with or without sten
mesenteric ischemia from 2000-2006
Variable
Chronic mesenteric is
PTA/S Surgerya
All patients 3.7 15.4
With bypass . . . 13.1
Mortality within subgroups
Age, years
60 0.7 8.8
60-70 2.4 14.8
70-80 3.8 14.1
80 6.8 39.2
Sex
Female 3.6 15.8
Malec 4.2 13.9
Comorbidity
Hypertension 2.9 9.2
PVD 1.8 13.7
CAD 2.2 16.4
AFib/flutter 11.5 35.9
Prior MI 1.8 3.7
CHF 9.9 38.8
Diabetes mellitus 4.1 12.6
COPD 5.0 17.8
Chronic renal disease 4.9 17.9
CVD 2.3 23.9
Bowel resection 24.6 55.3
With bypass . . . 53.9
AFib, Atrial fibrillation; CAD, coronary artery disease; CHF, congestive he
disease; MI, myocardial infarction; PTA/S, percutaneous transluminal angi
deviation.
aSurgery includes bypass, endarterectomy, or embolectomy.
bStatistical significance set at P  .01.
cP  NS for mortality of males vs females for each repair type.
Table III. Perioperative complications and length of stay
surgical repair for chronic and acute mesenteric ischemia fr
Complication
Chronic mesenteric ischemia
PTA/S Surgery a Pb Bypass
Any complication, % 20.2 39.7 .001 38.
Bowel resection, % 3.0 8.0 .001 6.
Acute renal failure, % 6.0 10.5 .01 9.
Acute MI, % 3.0 4.8 .13 3.
Cardiac, % 0.7 5.9 .001 5.
Stroke, % 0 0.7 .05 0.
PVD, % 0.8 0.2 .25.28 0.
Respiratory, % 0.3 5.3 .001 5.
Hemorrhage, % 1.3 3.4 .05 3.
LOS, median
(range), d
5 (0-94) 11 (1-135) .001 11 (1-1
LOS, Length of stay; MI, myocardial infarction; PTA/S, percutaneous trans
aSurgery includes bypass, endarterectomy, or embolectomy.
bStatistical significance set at P  .01.IV). Increasing age was also a predictor of death, with a 50%increased risk per decade of life. Comorbidities that were
predictive of death included congestive heart failure and
atrial fibrillation/flutter, with a greater than twofold in-
creased risk for both. Hypertension was protective.
AMI from 2000 to 2006. Surgical revascularization
, compared with surgical repair for chronic and acute
a, % Acute mesenteric ischemia, %
Pb PTA/S Surgerya Pb
.001 15.6 38.6 .001
.001 27.6 .001
.01 14.4 22.3 .13
.001 12.9 28.2 .01
.001 12.5 46.1 .001
.001 24.8 59.9 .001
.001 15.4 41.0 .001
.01 16.2 34.0 .001
.001 13.1 41.3 .001
.001 10.2 39.7 .001
.001 10.2 45.0 .001
.001 28.9 49.2 .001
.59 12.5 39.1 .05
.001 28.2 44.6 .05
.05 11.6 38.0 .001
.001 16.3 41.3 .001
.26 19.4 49.0 .05
.01 11.6 32.2 .11
.05 28.8 46.5 .01
.05 45.4 .05
ure; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular
, with or without stenting; PVD, peripheral vascular disease; SD, standard
angioplasty, with or without stenting, compared with
000 to 2006
Acute mesenteric ischemia
Pb PTA/S Surgery a Pb Bypass only Pb
001 36.7 48.2 .001 49.9 .001
.05 . . . . . . . . . . . . . . .
.05 11.4 18.4 .01 16.8 .05
.61 5.0 7.6 .10 4.4 .73
.001 2.1 7.2 .001 9.3 .001
.05 1.0 0.3 .11 0.3 .24
0.5 0.3 .58 0.7 .79
.001 1.1 5.7 .001 8.8 .001
.05 2.4 2.7 .74 3.1 .59
.001 9 (0-104) 13 (0-198) .001 14 (1-127) .001
al angioplasty, with or without stenting; PVD, peripheral vascular disease.ting
chemi
art fail
oplastyafter
om 2
only
4
6
7
6
6
8
3
7
4
35)
luminfor AMI consisted of 49% embolectomy, 44% bypass, and
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for AMI tended to be older women with multiple comor-
bidities. Those undergoing PTA/S for AMI also had
higher rates of comorbidities than those undergoing open
surgical repair, including hypertension, peripheral vascular
disease, coronary artery disease, atrial fibrillation/flutter,
and chronic renal failure (Table I). Atrial fibrillation and
flutter were more common for AMI than CMI, as expected
(33% vs 16%, P  .001). Bowel resection occurred in 28%
of patients undergoing PTA/S and 37% of those undergo-
ing bypass (P  .05). In-hospital mortality was 16% after
PTA/S and 39% after surgical repair for AMI (P  .001).
Mortality was 49% for embolectomy, 28% for bypass, and
35% for endarterectomy. When comparison with PTA/S
was limited to bypass, mortality was still significantly lower
with PTA/S (P .001). There was a trend for men to have
a lower mortality than women after open repair (34% vs
41%, P  .07); however, mortality by gender was similar
after PTA/S (16% vs 15%, P  .85). Mortality was again
increased for both groups when bowel resection was per-
formed during the same admission (bypass, 45% vs 17%,
P  .001; PTA/S, 29% vs 11%, P  .001).
Overall morbidity for AMI was higher after bypass
compared with PTA/S (Table III). Specifically, cardiac and
respiratory complications were again significantly higher.
Length of stay was shorter after PTA/S than bypass, with a
mean of 9 days (range, 0-104 days) vs 14 days (range,
1-127; P  .001). Discharge disposition to home was
similar, at 72% for PTA/S and 68% for bypass (P  .37).
Multivariate predictors of mortality for AMI included
Table IV. Multivariate predictors of death after
angioplasty, with or without stenting, compared with
mesenteric bypass for chronic and acute mesenteric
ischemia from 2000 to 2006
Predictor OR 95% CI Pa
Without comorbidities
Chronic mesenteric ischemia
Bypass (vs PTA/S) 5.1 3.1-8.4 .001
Age (per decade) 1.6 1.2-2.0 .001
Acute mesenteric ischemia
Bypass (vs PTA/S) 2.2 1.5-3.3 .001
Age (per decade) 1.3 1.1-1.6 .001
With comorbidities
Chronic mesenteric ischemia
Bypass (vs PTA/S) 5.7 3.3-9.8 .001
Age (per decade) 1.5 1.1-2.0 .01
Hypertension 0.4 0.2-0.7 .001
Atrial fibrillation/flutter 2.5 1.4-4.5 .01
Congestive heart failure 2.8 1.5-5.3 .01
Acute mesenteric ischemia
Bypass (vs PTA/S) 2.2 1.5-3.4 .001
Age (per decade) 1.3 1.02-1.5 .05
Bowel resection 3.6 2.4-5.4 .001
Atrial fibrillation/flutter 2.2 1.3-3.4 .001
CI, Confidence interval; OR, odds ratio; PTA/S, percutaneous transluminal
angioplasty, with or without stenting.
aStatistical significance set at P  .01.bypass vs PTA/S and age (Table IV). With comorbiditiesincluded, the need for a bowel resection and atrial fibrilla-
tion/flutter were also significant predictors. Bypass was
associated with a greater than twofold increased risk of
death, and the need for a bowel resection carried a greater
than 3.5-fold increased risk. Bowel resection was included
in the multivariate analysis for AMI (but not CMI) as a
coexisting condition. Gender was not a significant predic-
tor of mortality.
DISCUSSION
Revascularization for CMI and AMI is increasingly
being performed with PTA/S. PTA/S for CMI is associ-
ated with a lower in-hospital mortality rate, shorter length
of stay, and fewer bowel resections. For AMI, bypass was
typically done in more advanced cases requiring bowel
resection, making comparison with PTA/S difficult. After
controlling for the need for bowel resection, however,
there was a lower mortality rate with PTA/S. Revascular-
ization procedures for CMI are increasing overall, with a
dramatic rise in PTA/S and a constant rate of surgical
procedures, whereas revascularization for AMI is relatively
constant, with PTA/S apparently replacing surgery in some
cases.
The increase in revascularization procedures for CMI
may be due to many reasons. There may be increasing
awareness of the disease, particularly now that a minimally
invasive treatment is available and being more widely used.
The advancing age of the population may be contributing,
although this would also be expected to demonstrate a rise
in AMI as well unless the increase in elective procedures is
preventing AMI.With the less invasive approach, treatment
indicationsmay be expanding to include patients previously
considered to be at prohibitive risk for surgery. PTA/S
patients in this series were older with greater comorbidity.
In addition, indications may have expanded to include
treatment of those with symptoms that are less severe or
those in whom the diagnosis is in question. If this is the
case, this may bias the results in favor of PTA/S, whereas
treatment of those at prohibitive risk for surgery would
potentially bias in favor of surgery. Finally, it is well docu-
mented that PTA/S is associated with a greater risk of
restenosis and recurrent symptoms,15 which is certainly
having some effect in the increase in overall CMI interven-
tions. In addition, patients undergoing repeat intervention
for restenosis may have a different risk for in-hospital mor-
tality and could again influence the comparison of PTA/S
with surgery.
Longitudinal follow-up is needed to determine whe-
ther PTA/S has any long-term benefit compared with
surgery. Some have suggested that a strategy of initial
PTA/S would allow for correction of the malnourished
state so that the patient may more safely undergo surgical
revascularization after the early onset of recurrent steno-
sis and symptoms before a severe deterioration in nutri-
tional status.12,23
The decline in surgical procedures for AMI appears to
be primarily in those undergoing embolectomy, which is
likely due to an increasing use of anticoagulation for dys-
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Mayo Clinic found an increase in rates of anticoagulation
and a decrease in embolic strokes in patients with atrial
fibrillation between 1980 and 2000.24
A recent review by Kougias et al15 summarized the
largest series of PTA/S for CMI. They found a 30-day
mortality rate of 3% and a restenosis rate of 28% at a mean
follow-up of 2 years, with 27% undergoing repeat PTA/S.
The mortality rate from large series of open revasculariza-
tion for CMI ranged from 0% to 12%.1-7,13,14 The broad
range reflects the small number of patients undergoing
revascularization for CMI, even at large referral centers.
Derrow et al8 reviewed the NIS database for surgical revas-
cularization of CMI from 1993 to 1997 and found a
mortality rate of 14.7%, which corresponds to our findings
from a broader period using the same database.8 Therefore,
the numbers from the current study better reflect the true
risk of open surgical revascularization and demonstrate the
potential benefit of PTA/S.
Mortality with revascularization for AMI is typically
50%.1,5,9,10 We found that the surgical revascularization
mortality rate was highest with embolectomy and lowest
with bypass. This is likely due to the lack of an established
collateral circulation with embolization. Because most be-
lieve PTA/S is inappropriate treatment for most cases of
embolism, we focused on a comparison of PTA/S with
bypass.
We found that the need for bowel resection was the
primary predictor of death with AMI more so than the use
of PTA/S vs bypass. Unlike CMI, the need for bowel
resection with AMI likely reflects the severity of ischemia at
the time of the vascular consultation rather than a compli-
cation of revascularization.9,10 Given that resection was
required in a much larger proportion of those undergoing
bypass, the two cohorts are likely dissimilar, which biases
the comparison in favor of PTA/S.
There is general agreement that in most cases of AMI,
bowel viability needs to be inspected and resection per-
formed as needed. The diagnosis of AMI is often made at
laparotomy in an operating room setting that may not be
amenable for angiography and intervention that may limit
the broader application of this technology. Retrograde
stenting of the superior mesenteric artery through an arte-
riotomy has been advocated as a means to provide rapid
revascularization through the open abdomen at the time of
laparotomy.18,21,22We do not have the ability to determine
whether percutaneous antegrade or open retrograde
PTA/S was used in patients undergoing laparotomy in the
NIS database and cannot comment on the potential merits
of this approach.
With the expansion of operating room endovascular
suites and the increasing use of rapid multiple row detector
computed tomographic angiography for diagnosis, PTA/S
may be used with greater frequency when the diagnosis is
entertained before laparotomy. However, PTA/S would
not be expected to obviate the need to inspect bowel
viability.Our study has several limitations. This is a retrospective
study with clear selection bias in the choice of therapy. This
is most evident in AMI, where more patients with advanced
ischemia underwent bypass than PTA/S. Other factors that
were unmeasured in addition to the need for bowel resec-
tion may have affected the decision to choose bypass rather
than PTA/S. We do not have anatomic details about the
number of vessels treated, lesion length, or stenosis vs
occlusion, which are likely to impact revascularization strat-
egy and could affect outcome.
The large numbers in this study (20% sample of non-
federal hospitals) obtained from hospital discharge data are
the strength of the study. This is evidenced by a comparison
with the recent review of the literature of mesenteric
PTA/S by Kougias et al15 with a total of 292 patients that
would represent a 5% sample of patients undergoing this
procedure. Discharge databases such as NIS are subject to
coding errors, however, which are highlighted by the 3% of
patients who were coded as undergoing embolectomy for
CMI. A nearly threefold higher percentage of CMI patients
undergoing embolectomy had atrial fibrillation/flutter
compared with those undergoing another method of re-
pair. In addition, the diagnosis of CMI is often a difficult
one and may be made without a complete workup, partic-
ularly when percutaneous therapy is attempted. We also
cannot identify patients undergoing repeat mesenteric pro-
cedures.
The increasing number of endovascular procedures
may be reflective of either of these and bias mortality in
favor of PTA/S. The inability to definitively state whether a
bowel resection is done at the time of mesenteric operation,
during a “second look” procedure, before revasculariza-
tion, or as a complication of the mesenteric operation is one
more limitation of the NIS database. There is a variable for
day of operation, but this was infrequently recorded and
thus was an unreliable method to further clarify this.
CONCLUSION
There is a clear trend toward increasing use of PTA/S
for CMI and AMI. PTA/S appears to be reasonable first-
line therapy in selected patients, particularly in CMI, based
on significantly lower in-hospital mortality and complica-
tions. Longitudinal data are needed to determine if this
benefit is maintained over time. Further data with greater
detail regarding symptomatology and anatomy will clarify
appropriate patient selection.
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comorbidities and complications
ICD-9 Codes
Comorbidities
Hypertension 401-405
Peripheral vascular disease 440, 443
Coronary artery disease 412-414
Cardiac dysrhythmias 427
Atrial fibrillation/flutter 427.3
Prior myocardial infarction 412
Congestive heart failure 428
Diabetes mellitus 250
Chronic obstructive pulmonary disease 491, 491, 492, 496
Chronic renal disease 585, 586, V45.1, V56
Cerebrovascular disease 433-438
Bowel resection 45.5, 45.6, 45.7, 45.8, 45.9, 46.1, 46.2, 48.5
Complications
Acute renal failure 584
Acute myocardial infarction 410
Not elsewhere classified 996-999
Stroke 997.02
Cardiac 997.1
Peripheral vascular 997.2
Respiratory 997.3
Hemorrhage 998.11
